tiprankstipranks
Trending News
More News >
Allurion Technologies, Inc. (ALUR)
:ALUR
US Market
Advertisement

Allurion Technologies (ALUR) Earnings Dates, Call Summary & Reports

Compare
297 Followers

Earnings Data

Report Date
Mar 19, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-0.91
Last Year’s EPS
-7.95
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 12, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call highlighted significant progress in the FDA approval process and successful restructuring efforts that improved financial efficiencies. However, these positives were tempered by a considerable decline in revenue and gross profit. The company's strategic initiatives, such as debt restructuring and R&D advancements, indicate a positive long-term outlook.
Company Guidance
In the third quarter earnings call, Allurion Technologies provided several updates and metrics regarding its financial performance and strategic initiatives. The company reported a revenue of $2.7 million, reflecting a restructuring to focus on accounts promoting metabolically healthy weight loss. Operating expenses decreased by 29% to $10.9 million, narrowing the operating loss to $9.6 million, a 22% improvement from the previous year. Adjusted operating expenses were $8.4 million, and adjusted net operating loss was $6.9 million, both showing significant improvements from the prior year. Allurion also highlighted its progress toward FDA approval for the Allurion Smart Capsule, passing critical milestones such as the pre-approval and BIMO inspections with no observations. Furthermore, the company announced plans to restructure its balance sheet, aiming to be debt-free, and has initiated a transaction to exchange outstanding debt for convertible preferred equity. The strategic pivot to focus on combination therapy with GLP-1s and the development of a drug-eluting balloon as part of its R&D pipeline were emphasized as key components of Allurion's future growth strategy.
FDA Approval Process Milestones
Allurion passed several critical milestones towards FDA approval for the Allurion Smart Capsule, including the completion of the substantive review phase with no observations or Form 483 issued, indicating readiness for the U.S. market.
Restructuring Success
Operating expenses decreased by 29%, and operating loss narrowed by 22% compared to the prior year, reflecting improved efficiencies from restructuring efforts.
Debt Restructuring and Financial Position
Allurion entered a transaction to exchange all outstanding debt for convertible preferred equity, along with a $5 million private placement financing, strengthening the financial position and providing a path to being debt-free.
R&D and Manufacturing Innovations
Exploration of a drug-eluting balloon in collaboration with a strategic partner, with potential to revolutionize obesity therapy by addressing adherence challenges.

Allurion Technologies (ALUR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ALUR Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 19, 2026
2025 (Q4)
-0.91 / -
-7.95
Nov 12, 2025
2025 (Q3)
-1.97 / -1.53
-3.556.29% (+1.97)
Aug 13, 2025
2025 (Q2)
-0.89 / -1.28
-1.25-2.40% (-0.03)
May 14, 2025
2025 (Q1)
-1.57 / 1.46
2.75-47.02% (-1.29)
Mar 26, 2025
2024 (Q4)
-5.70 / -7.95
-1020.50% (+2.05)
Nov 13, 2024
2024 (Q3)
-4.56 / -3.50
-13.40873.90% (+9.91)
Aug 13, 2024
2024 (Q2)
-6.00 / -1.25
-73.96898.31% (+72.72)
May 14, 2024
2024 (Q1)
-7.00 / 2.75
-10.8125.46% (+13.55)
Mar 21, 2024
2023 (Q4)
-12.70 / -10.00
0.32-3225.00% (-10.32)
Nov 13, 2023
2023 (Q3)
- / -13.41
1.962-783.38% (-15.37)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ALUR Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 12, 2025
$1.49$1.50+0.67%
Aug 13, 2025
$2.58$2.54-1.55%
May 14, 2025
$2.36$2.92+23.73%
Mar 26, 2025
$3.11$3.12+0.32%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Allurion Technologies, Inc. (ALUR) report earnings?
Allurion Technologies, Inc. (ALUR) is schdueled to report earning on Mar 19, 2026, Before Open (Confirmed).
    What is Allurion Technologies, Inc. (ALUR) earnings time?
    Allurion Technologies, Inc. (ALUR) earnings time is at Mar 19, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ALUR EPS forecast?
          ALUR EPS forecast for the fiscal quarter 2025 (Q4) is -0.91.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis